Medical Scientific Experts Presentation Tips for Medical Scientific Experts Example: Canephron Effective and magnetic presentations Speaker-Training-Bionorica-Examples © Dr. Günter Umbach www.umbachpartner.com

Scientific Data: Publication Overall, the present clinical trial lends further support to the viability of symptomatic treatment alternatives of acute lower uncomplicated urinary tract infections to antibiotics by demonstrating non-inferiority of a herbal treatment alternative, which had fewer gastrointestinal side effects such as diarrhoea and abdominal pain compared to antibiotics. This trial may encourage wider adoption of antibiotic alternatives, such as Canephron for the treatment of lower uncomplicated urinary tract infections in routine clinical practice. Non-Antibiotic Herbal Therapy (BNO 1045) versus Antibiotic Therapy (Fosfomycin Trometamol) for the Treatment of Acute Lower Uncomplicated Urinary Tract Infections in Women: A Double-Blind, Parallel-Group, Randomized, Multicentre, Non-Inferiority Phase III Trial Urol Int, DOI: 10.1159/000493368

Background Patients with acute lower uncomplicated urinary tract infections are often treated with antibiotics.

Research Question Can we demonstrate the non-inferiority of BNO 1045 for 7 days of treatment versus a single dose of FT in women, as measured by the proportion of patients who received an additional AB? = Would a herbal treatment with Canephron be an effective alternative?

Results: Text The majority of patients did not take an additional AB between Days 1 and 38 in the BNO 1045 group (n = 238; 83.5%) and the FT group (n = 272; 89.8%)

Results: Table Fosfomycin Canephron 89.9 83.5 Patients not taking an additional antibiotic between Days 1 and 38 in the BNO 1045 (Canephron) group (n = 238; 83.5%) and the Fosfomycin group (n = 272; 89.8%)

Print Scanned Diagram Non-inferiority of BNO 1045 vs FT (non-AB rate) in the Per Protocol Set (PPS). Percentages are the proportion of patients within each respective treatment group who did not take AB between Day 1 and 38 ± 3.

Print Scanned Diagram

89.8 83.5 Canephron Group % of patients Fosfomycin Group Fosfomycin vs Canephron in lower uncomplicated urinary tract infections Better Diagram - - 80 Non- inferiority Margin -------------------------------------------------------------------------------- - - 89.8 83.5 60 % of patients - - 40 - - 20 - Fosfomycin Group Canephron Group Similar percentages of patients not needing an additional antibiotic Urol Int, DOI: 10.1159/ 000493368

Wording The trial shows non-inferiority The two treatment options are equivalent The two treatment options are comparable

Conclusion This trial encourages wider adoption of antibiotic alternatives, such as Canephron, for treating lower uncomplicated urinary tract infections in clinical practice.

Medical Scientific Experts Example: Sinupret extract Presentation Tips for Medical Scientific Experts Example: Sinupret extract Effective and magnetic presentations Speaker-Training-Bionorica-Examples © Dr. Günter Umbach www.umbachpartner.com

Results: Scanned Diagram Print Results: Scanned Diagram

Numbers Fig. 1

Wording Significant Clear Substantial

Wording Reduction in complaints Clinical improvement

p value p < 0.0001 p < 0.01

Rhinosinusitis Treatment Mean Major Symptom Score (MMS) Better Diagram Rhinosinusitis Treatment Mean Major Symptom Score (MMS) p < 0.01 3.6 MMS 2.5 Placebo Sinupret Sinupret is an effective therapy for rhinosinusitis Jund, R., et al.: Clinical efficacy of a dry extract of five herbal drugs in acute viral rhinosinusitis. Rhinology 50(4) (2012), 417–426

Answer the Question How? Mode of Action Mode of Action

Sinupret: Pharmacological Properties • Secretolytic • Anti-inflammatory • Antiviral and antibacterial features Mode of Action